Tobacco Use Disorder
Conditions
Brief summary
The investigators propose an innovative full-factorial design in a cohort of 1056 adult smokers in an urban emergency department (ED), to test the efficacy of four key intervention components: motivational interviewing, medication, quitline referral, and texting. At the trial's completion, a mixed-methods approach will be used to identify the components that were efficacious within the proposed cost constraint, along with feasibility and acceptability to providers and subjects. The investigators will then assemble an intervention that maximizes efficacy, given a cost-effectiveness constraint and findings from a qualitative analysis.
Detailed description
The investigators propose to optimize the identification and treatment of adult smokers seen in a hospital ED. To do this the Multiple Optimization Strategy (MOST) will be employed to develop a multicomponent intervention that will consist of some combination of the following: (1) a Brief Negotiation Interview (BNI, a variant of a motivational interview), delivered by a trained research assistant; (2) provision of 6 weeks of nicotine patches and gum to the research participant, with application of the first patch in the ED (NRT); (3) active referral to the Connecticut Smokers' Quitline (QL); and (4) enrollment in the SmokefreeText a short-messaging service (SMS) texting program for mobile phones (Text). Using MOST principles, the first phase of the study will use a 2x2x2x2 full-factorial design to identify the components most likely to be efficacious in combination. Although the factorial design requires the allocation of participants to 16 different combinations of the 4 components (Table 1), evaluation of each individual component is performed comparing all of those receiving a component to all of those not receiving a component, making this an efficient design. For instance, evaluation of the BNI component will compare those randomized to arms 1 through 8 to those in arms 9 to 16.The second phase will consist of designing and proposing a 2-arm randomized clinical trial comparing the efficacy of the multicomponent intervention package to usual care; this will be conducted in a future application. The specific aims of this proposed study are: Aim 1. To conduct a fully powered factorial randomized trial of 1056 adult smokers to test the efficacy of 4 key components of ED-initiated tobacco treatment: Brief Negotiated Interview (BNI), nicotine replacement therapy (NRT), Quitline referral (QL), and SmokeFreeText (Text). Aim 2. To identify the most efficacious components of our intervention, within fixed constraints of cost effectiveness and feasibility/acceptability to providers and subjects. Aim 3. To lay the groundwork for a future randomized trial testing the previously identified components, delivered as a package, against a control arm in a new cohort of adult ED smokers. Our associated hypotheses are: 1. At 3 months, at least 1 intervention component will yield a biochemically verified tobacco abstinence rate at least 5% greater than in the control condition. Carbon monoxide breath test will be used for biochemical verification. 2. At 3 months, at least 1 intervention will be cost-effective, using a societal perspective. 3. At 3 months, at least 1 intervention will be acceptable and feasible to providers and subjects.
Interventions
Brief motivational interview on smoking behavior
6 weeks of nicotine replacement, patches and gum. First dose of each started in ED. Patches are 14mg or 21 mg. Gum is 2mg per piece.
Faxed referral to the CT Smokers Quitline for the subject. QL will then call subject to offer phone based counseling.
Enrollment in a version of NCI's SmokefreeTxt, tailored for the study.
Sponsors
Study design
Eligibility
Inclusion criteria
* 18 years or older * have smoked \>= 100 cigarettes lifetime * describe themselves as every or some day smokers * smoke at least 5 cigarettes/day * own a cellphone with texting capability * are able to give written informed consent
Exclusion criteria
* Inability to read or understand English * currently receiving formal tobacco dependence treatment * life-threatening or unstable medical, surgical, or psychobehavioral condition * unable to provide at least one collateral contact * live out-of-state * leaving the ED against medical advice * pregnant (self-report or urine testing), nursing, or trying to conceive.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Tobacco Abstinence | 3 months | Abstinence self reported and verified by exhaled carbon monoxide |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| NRT+QL+Text Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
Nicotine replacement therapy (NRT): 6 weeks of nicotine replacement, patches and gum. First dose of each started in ED. Patches are 14mg or 21 mg. Gum is 2mg per piece.
CT Smokers Quitline (QL): Faxed referral to the CT Smokers Quitline for the subject. QL will then call subject to offer phone based counseling.
SmokefreeText (Text): Enrollment in a version of NCI's SmokefreeTxt, tailored for the study. | 66 |
| BNI+QL+Text Brief Negotiated Interview (BNI) Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
Brief Negotiated Interview (BNI): Brief motivational interview on smoking behavior
CT Smokers Quitline (QL): Faxed referral to the CT Smokers Quitline for the subject. QL will then call subject to offer phone based counseling.
SmokefreeText (Text): Enrollment in a version of NCI's SmokefreeTxt, tailored for the study. | 66 |
| BNI+NRT+QL+Text Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
Brief Negotiated Interview (BNI): Brief motivational interview on smoking behavior
Nicotine replacement therapy (NRT): 6 weeks of nicotine replacement, patches and gum. First dose of each started in ED. Patches are 14mg or 21 mg. Gum is 2mg per piece.
CT Smokers Quitline (QL): Faxed referral to the CT Smokers Quitline for the subject. QL will then call subject to offer phone based counseling.
SmokefreeText (Text): Enrollment in a version of NCI's SmokefreeTxt, tailored for the study. | 66 |
| NRT+QL Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL)
Nicotine replacement therapy (NRT): 6 weeks of nicotine replacement, patches and gum. First dose of each started in ED. Patches are 14mg or 21 mg. Gum is 2mg per piece.
CT Smokers Quitline (QL): Faxed referral to the CT Smokers Quitline for the subject. QL will then call subject to offer phone based counseling. | 66 |
| BNI+QL Brief Negotiated Interview (BNI) Referral to CT Smokers Quitline (QL)
Brief Negotiated Interview (BNI): Brief motivational interview on smoking behavior
CT Smokers Quitline (QL): Faxed referral to the CT Smokers Quitline for the subject. QL will then call subject to offer phone based counseling. | 66 |
| NRT Only Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply
Nicotine replacement therapy (NRT): 6 weeks of nicotine replacement, patches and gum. First dose of each started in ED. Patches are 14mg or 21 mg. Gum is 2mg per piece. | 66 |
| BNI+Text Brief Negotiated Interview (BNI) Registration in SmokefreeText (Text)
Brief Negotiated Interview (BNI): Brief motivational interview on smoking behavior
SmokefreeText (Text): Enrollment in a version of NCI's SmokefreeTxt, tailored for the study. | 66 |
| BNI+NRT+Text Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Registration in SmokefreeText (Text)
Brief Negotiated Interview (BNI): Brief motivational interview on smoking behavior
Nicotine replacement therapy (NRT): 6 weeks of nicotine replacement, patches and gum. First dose of each started in ED. Patches are 14mg or 21 mg. Gum is 2mg per piece.
SmokefreeText (Text): Enrollment in a version of NCI's SmokefreeTxt, tailored for the study. | 66 |
| NRT+Text Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Registration in SmokefreeText (Text)
Nicotine replacement therapy (NRT): 6 weeks of nicotine replacement, patches and gum. First dose of each started in ED. Patches are 14mg or 21 mg. Gum is 2mg per piece.
SmokefreeText (Text): Enrollment in a version of NCI's SmokefreeTxt, tailored for the study. | 66 |
| BNI+NRT Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply
Brief Negotiated Interview (BNI): Brief motivational interview on smoking behavior
Nicotine replacement therapy (NRT): 6 weeks of nicotine replacement, patches and gum. First dose of each started in ED. Patches are 14mg or 21 mg. Gum is 2mg per piece. | 66 |
| Control Control arm, no intervention | 66 |
| BNI+NRT+QL Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL)
Brief Negotiated Interview (BNI): Brief motivational interview on smoking behavior
Nicotine replacement therapy (NRT): 6 weeks of nicotine replacement, patches and gum. First dose of each started in ED. Patches are 14mg or 21 mg. Gum is 2mg per piece.
CT Smokers Quitline (QL): Faxed referral to the CT Smokers Quitline for the subject. QL will then call subject to offer phone based counseling. | 66 |
| Text Only Registration in SmokefreeText (Text)
SmokefreeText (Text): Enrollment in a version of NCI's SmokefreeTxt, tailored for the study. | 66 |
| QL+Text Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
CT Smokers Quitline (QL): Faxed referral to the CT Smokers Quitline for the subject. QL will then call subject to offer phone based counseling.
SmokefreeText (Text): Enrollment in a version of NCI's SmokefreeTxt, tailored for the study. | 66 |
| BNI Only Brief Negotiated Interview (BNI)
Brief Negotiated Interview (BNI): Brief motivational interview on smoking behavior | 66 |
| QL Only Referral to CT Smokers Quitline (QL)
CT Smokers Quitline (QL): Faxed referral to the CT Smokers Quitline for the subject. QL will then call subject to offer phone based counseling. | 66 |
| Total | 1,056 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 | FG008 | FG009 | FG010 | FG011 | FG012 | FG013 | FG014 | FG015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 Month Follow-up | Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| 1 Month Follow-up | Lost to Follow-up | 7 | 7 | 5 | 8 | 9 | 6 | 5 | 6 | 4 | 7 | 5 | 5 | 3 | 4 | 1 | 2 |
| 3 Month Follow-up | Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| 3 Month Follow-up | Lost to Follow-up | 6 | 3 | 6 | 11 | 12 | 6 | 4 | 3 | 6 | 5 | 6 | 6 | 3 | 5 | 3 | 2 |
| Biochemical Verification at 3 Months | Lost to Follow-up | 1 | 0 | 1 | 1 | 0 | 1 | 3 | 2 | 1 | 1 | 0 | 0 | 1 | 0 | 3 | 1 |
| Biochemical Verification at 3 Months | participant was not eligible for biochem | 45 | 48 | 46 | 40 | 45 | 48 | 48 | 47 | 44 | 52 | 55 | 41 | 52 | 48 | 52 | 56 |
Baseline characteristics
| Characteristic | BNI+QL+Text | Total | QL Only | BNI Only | QL+Text | Text Only | BNI+NRT+QL | Control | BNI+NRT | NRT+Text | BNI+NRT+Text | BNI+Text | NRT Only | BNI+QL | NRT+QL | NRT+QL+Text | BNI+NRT+QL+Text |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 41.33 years STANDARD_DEVIATION 11.92 | 43.26 years STANDARD_DEVIATION 12.12 | 43.21 years STANDARD_DEVIATION 11.77 | 41.86 years STANDARD_DEVIATION 10.42 | 42.36 years STANDARD_DEVIATION 12.49 | 44.33 years STANDARD_DEVIATION 12.23 | 43.18 years STANDARD_DEVIATION 10.67 | 43.65 years STANDARD_DEVIATION 14 | 44.30 years STANDARD_DEVIATION 13.23 | 43.67 years STANDARD_DEVIATION 12.6 | 43.77 years STANDARD_DEVIATION 11.8 | 42.64 years STANDARD_DEVIATION 12.42 | 42.26 years STANDARD_DEVIATION 12.27 | 40.56 years STANDARD_DEVIATION 11.97 | 43.73 years STANDARD_DEVIATION 12.14 | 46.86 years STANDARD_DEVIATION 10.72 | 44.36 years STANDARD_DEVIATION 12.75 |
| Cigarettes per Day (CPD) | 12.0 cigarettes per day | 10.0 cigarettes per day | 10.0 cigarettes per day | 10.0 cigarettes per day | 10.0 cigarettes per day | 10.0 cigarettes per day | 11.0 cigarettes per day | 10.0 cigarettes per day | 10.0 cigarettes per day | 9.0 cigarettes per day | 10.0 cigarettes per day | 10.0 cigarettes per day | 10.0 cigarettes per day | 10.0 cigarettes per day | 10.0 cigarettes per day | 10.0 cigarettes per day | 10.0 cigarettes per day |
| Ethnicity (NIH/OMB) Hispanic or Latino | 15 Participants | 231 Participants | 10 Participants | 14 Participants | 19 Participants | 13 Participants | 14 Participants | 13 Participants | 23 Participants | 14 Participants | 10 Participants | 19 Participants | 9 Participants | 15 Participants | 22 Participants | 14 Participants | 7 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 51 Participants | 807 Participants | 56 Participants | 52 Participants | 45 Participants | 51 Participants | 49 Participants | 52 Participants | 43 Participants | 51 Participants | 55 Participants | 45 Participants | 55 Participants | 51 Participants | 43 Participants | 52 Participants | 56 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 18 Participants | 0 Participants | 0 Participants | 2 Participants | 2 Participants | 3 Participants | 1 Participants | 0 Participants | 1 Participants | 1 Participants | 2 Participants | 2 Participants | 0 Participants | 1 Participants | 0 Participants | 3 Participants |
| Heaviness of Smoking Index >=4 | 28 participants | 270 participants | 12 participants | 17 participants | 13 participants | 19 participants | 21 participants | 15 participants | 21 participants | 13 participants | 13 participants | 20 participants | 23 participants | 9 participants | 18 participants | 15 participants | 13 participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants | 15 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 3 Participants | 1 Participants | 0 Participants | 1 Participants | 1 Participants | 1 Participants | 0 Participants | 2 Participants | 1 Participants | 2 Participants | 1 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 3 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 25 Participants | 401 Participants | 29 Participants | 19 Participants | 28 Participants | 29 Participants | 26 Participants | 27 Participants | 19 Participants | 23 Participants | 23 Participants | 23 Participants | 24 Participants | 26 Participants | 22 Participants | 24 Participants | 34 Participants |
| Race (NIH/OMB) More than one race | 5 Participants | 63 Participants | 2 Participants | 10 Participants | 5 Participants | 2 Participants | 0 Participants | 7 Participants | 5 Participants | 2 Participants | 5 Participants | 4 Participants | 6 Participants | 2 Participants | 5 Participants | 0 Participants | 3 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 9 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 2 Participants | 1 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 28 Participants | 3 Participants | 2 Participants | 4 Participants | 5 Participants | 0 Participants | 2 Participants | 1 Participants | 1 Participants | 1 Participants | 1 Participants | 0 Participants | 2 Participants | 3 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) White | 33 Participants | 537 Participants | 31 Participants | 34 Participants | 28 Participants | 30 Participants | 35 Participants | 29 Participants | 40 Participants | 37 Participants | 35 Participants | 36 Participants | 36 Participants | 33 Participants | 35 Participants | 39 Participants | 26 Participants |
| Region of Enrollment United States | 66 Participants | 1056 Participants | 66 Participants | 66 Participants | 66 Participants | 66 Participants | 66 Participants | 66 Participants | 66 Participants | 66 Participants | 66 Participants | 66 Participants | 66 Participants | 66 Participants | 66 Participants | 66 Participants | 66 Participants |
| Sex: Female, Male Female | 38 Participants | 536 Participants | 36 Participants | 31 Participants | 42 Participants | 33 Participants | 29 Participants | 35 Participants | 35 Participants | 41 Participants | 28 Participants | 34 Participants | 31 Participants | 28 Participants | 28 Participants | 32 Participants | 35 Participants |
| Sex: Female, Male Male | 28 Participants | 520 Participants | 30 Participants | 35 Participants | 24 Participants | 33 Participants | 37 Participants | 31 Participants | 31 Participants | 25 Participants | 38 Participants | 32 Participants | 35 Participants | 38 Participants | 38 Participants | 34 Participants | 31 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk | EG010 affected / at risk | EG011 affected / at risk | EG012 affected / at risk | EG013 affected / at risk | EG014 affected / at risk | EG015 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 | 1 / 66 | 1 / 66 | 1 / 66 |
| other Total, other adverse events | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 |
| serious Total, serious adverse events | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 | 0 / 66 |
Outcome results
Tobacco Abstinence
Abstinence self reported and verified by exhaled carbon monoxide
Time frame: 3 months
Population: All participants eligible for 3 month follow-up (deceased participants excluded). Each intervention group was compared with all participants who did not receive that intervention. The comparison group therefore differed for each intervention: BNI=526; NRT=525; QL=527; Text = 526.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Brief Negotiated Interview (BNI) | Tobacco Abstinence | 71 Participants |
| Brief Negotiated Interview (BNI) CONTROL | Tobacco Abstinence | 49 Participants |
| Nicotine Replacement Therapy (NRT) | Tobacco Abstinence | 76 Participants |
| Nicotine Replacement Therapy (NRT) CONTROL | Tobacco Abstinence | 44 Participants |
| Quitline (QL) | Tobacco Abstinence | 66 Participants |
| Quitline (QL) CONTROL | Tobacco Abstinence | 54 Participants |
| Text | Tobacco Abstinence | 61 Participants |
| Text CONTROL | Tobacco Abstinence | 59 Participants |